Back

Real-world effectiveness of mineralocorticoid receptor antagonists in heart failure with mildly reduced and preserved ejection fraction: a large southeast asian propensity-weighted cohort study

29 August 2026 (08:15 - 08:25)
Organised by: Logo
Congress Presentation Part of: Moving the needle further in HFrEF therapy Pharmacotherapy ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Porntep Amornritvanich

Police General Hospital, Bangkok (Thailand)

4 More presentations in this session

Presentation thumbnail
Efficacy of sacubitril/valsartan on mortality in asymptomatic hypotensive HFrEF: data from the China Cardiovascular Association Database-Heart Failure Center Registry
Doctor Z. Qiu (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
The FINO-HF trial: a randomised comparison of finerenone versus spironolactone in patients with heart failure with reduced ejection fraction - biomarker and clinical outcomes
Doctor R. Rascon Sabido (Veracruz, MX)
Abstract Slides Video
Presentation thumbnail
The LIRA-HF trial: liraglutide in heart failure with reduced ejection fraction and obesity – a 30-month randomized trial
Doctor R. Rascon Sabido (Veracruz, MX)
Abstract Slides Video
Presentation thumbnail
Glucagon-like peptide-1 receptor agonism in heart failure with improved ejection fraction; PRAISE-HFiEF
Assistant Professor I. Helmy (Cleveland, US)
Abstract Slides Video

Access the full session

Session thumbnail
Moving the needle further in HFrEF therapy
Video

The Event

Event poster

ESC Congress 2026

29 August 2026 08:15 CET
You may be interested in
thumbnail
Congress Session
Pharmacotherapy
23 May 2023
thumbnail
Congress Presentation
Comparative effectiveness of finerenone versus spironolactone in patients hospitalized with heart failure: a prospective cohort study
31 August 2026
thumbnail
Congress Presentation
Non-steroidal mineralocorticoid receptor antagonists (MRAs): standard therapy for HFpEF?
9 May 2026
thumbnail
Congress Session
Transforming heart failure with next-generation therapies and mechanisms
31 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources